Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 23.4 Million AUD | 27.07% |
| 2023 | 18.42 Million AUD | 21.69% |
| 2022 | 15.13 Million AUD | 2.7% |
| 2021 | 14.73 Million AUD | 46.38% |
| 2020 | 10.06 Million AUD | -19.28% |
| 2019 | 12.47 Million AUD | 12.4% |
| 2018 | 11.09 Million AUD | 63.86% |
| 2017 | 6.77 Million AUD | -20.21% |
| 2016 | 8.48 Million AUD | -20.02% |
| 2015 | 10.61 Million AUD | -14.48% |
| 2014 | 12.4 Million AUD | 62.42% |
| 2013 | 7.64 Million AUD | -2.62% |
| 2012 | 7.84 Million AUD | 29.97% |
| 2011 | 6.03 Million AUD | 18.0% |
| 2010 | 5.11 Million AUD | -41.31% |
| 2009 | 8.71 Million AUD | -34.09% |
| 2008 | 13.22 Million AUD | 15.03% |
| 2007 | 11.49 Million AUD | -5.57% |
| 2006 | 12.17 Million AUD | -15.74% |
| 2005 | 14.44 Million AUD | 29.05% |
| 2004 | 11.19 Million AUD | 99.82% |
| 2003 | 5.6 Million AUD | -3.22% |
| 2002 | 5.78 Million AUD | 64.62% |
| 2001 | 3.51 Million AUD | 733.56% |
| 2000 | 421.93 Thousand AUD | 627.42% |
| 1999 | -80 Thousand AUD | -11494.2% |
| 1998 | -690.00 AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 8.44 Million AUD | 100.38% |
| 2024 Q1 | 4.21 Million AUD | -45.41% |
| 2024 FY | 23.47 Million AUD | 27.43% |
| 2024 Q4 | 15.02 Million AUD | 0.0% |
| 2024 Q3 | 7.49 Million AUD | -11.29% |
| 2023 Q4 | 7.72 Million AUD | 114.93% |
| 2023 Q3 | 3.59 Million AUD | -66.43% |
| 2023 FY | 18.42 Million AUD | 21.69% |
| 2023 Q1 | 5.08 Million AUD | -51.31% |
| 2023 Q2 | 10.69 Million AUD | 110.52% |
| 2022 Q2 | 10.13 Million AUD | 131.87% |
| 2022 Q4 | 10.43 Million AUD | 137.25% |
| 2022 Q3 | 4.4 Million AUD | -56.57% |
| 2022 Q1 | 4.36 Million AUD | -55.58% |
| 2022 FY | 15.13 Million AUD | 2.7% |
| 2021 Q1 | 5.14 Million AUD | -17.44% |
| 2021 Q3 | 4.5 Million AUD | -53.05% |
| 2021 FY | 14.73 Million AUD | 46.38% |
| 2021 Q4 | 9.83 Million AUD | 118.13% |
| 2021 Q2 | 9.6 Million AUD | 86.66% |
| 2020 FY | 10.06 Million AUD | -19.28% |
| 2020 Q4 | 6.23 Million AUD | 118.18% |
| 2020 Q1 | 3.7 Million AUD | -68.18% |
| 2020 Q2 | 7.54 Million AUD | 103.58% |
| 2020 Q3 | 2.85 Million AUD | -62.11% |
| 2019 Q3 | 4.66 Million AUD | 20.32% |
| 2019 Q4 | 11.63 Million AUD | 149.61% |
| 2019 FY | 12.47 Million AUD | 12.4% |
| 2019 Q2 | 3.87 Million AUD | -0.0% |
| 2019 Q1 | 3.87 Million AUD | 21.51% |
| 2018 FY | 11.09 Million AUD | 63.86% |
| 2018 Q1 | 2.49 Million AUD | -0.37% |
| 2018 Q4 | 3.18 Million AUD | 0.0% |
| 2018 Q3 | 3.18 Million AUD | 27.82% |
| 2018 Q2 | 2.49 Million AUD | -0.0% |
| 2017 Q2 | 2.72 Million AUD | -0.0% |
| 2017 FY | 6.77 Million AUD | -20.21% |
| 2017 Q4 | 2.5 Million AUD | 0.0% |
| 2017 Q3 | 2.5 Million AUD | -8.06% |
| 2017 Q1 | 2.72 Million AUD | -19.81% |
| 2016 Q3 | 3.39 Million AUD | 21.48% |
| 2016 Q2 | 2.79 Million AUD | -0.0% |
| 2016 Q1 | 2.79 Million AUD | -25.96% |
| 2016 Q4 | 3.39 Million AUD | 0.0% |
| 2016 FY | 8.48 Million AUD | -20.02% |
| 2015 FY | 10.61 Million AUD | -14.48% |
| 2015 Q3 | 3.77 Million AUD | 65.22% |
| 2015 Q4 | 3.77 Million AUD | 0.0% |
| 2015 Q2 | 2.28 Million AUD | -0.0% |
| 2015 Q1 | 2.28 Million AUD | -60.88% |
| 2014 Q2 | 4.67 Million AUD | 0.0% |
| 2014 Q4 | 5.84 Million AUD | 0.0% |
| 2014 FY | 12.4 Million AUD | 62.42% |
| 2014 Q3 | 5.84 Million AUD | 24.95% |
| 2014 Q1 | 4.67 Million AUD | 66.31% |
| 2013 Q3 | 2.81 Million AUD | 0.0% |
| 2013 FY | 7.64 Million AUD | -2.62% |
| 2013 Q4 | 2.81 Million AUD | 0.0% |
| 2012 FY | 7.84 Million AUD | 29.97% |
| 2011 FY | 6.03 Million AUD | 18.0% |
| 2010 FY | 5.11 Million AUD | -41.31% |
| 2009 FY | 8.71 Million AUD | -34.09% |
| 2008 Q2 | 3.84 Million AUD | 0.0% |
| 2008 FY | 13.22 Million AUD | 15.03% |
| 2008 Q4 | -13.22 Million AUD | 0.0% |
| 2008 Q3 | - AUD | -100.0% |
| 2008 Q1 | - AUD | 100.0% |
| 2007 FY | 11.49 Million AUD | -5.57% |
| 2007 Q4 | -11.49 Million AUD | 0.0% |
| 2007 Q3 | - AUD | -100.0% |
| 2007 Q2 | 3.83 Million AUD | 0.0% |
| 2007 Q1 | - AUD | 100.0% |
| 2006 Q2 | 2.9 Million AUD | 0.0% |
| 2006 Q1 | - AUD | 100.0% |
| 2006 Q3 | - AUD | -100.0% |
| 2006 Q4 | -12.17 Million AUD | 0.0% |
| 2006 FY | 12.17 Million AUD | -15.74% |
| 2005 Q2 | 3.17 Million AUD | 0.0% |
| 2005 FY | 14.44 Million AUD | 29.05% |
| 2005 Q1 | - AUD | 100.0% |
| 2005 Q4 | -14.44 Million AUD | 0.0% |
| 2005 Q3 | - AUD | -100.0% |
| 2004 Q4 | -11.19 Million AUD | 0.0% |
| 2004 FY | 11.19 Million AUD | 99.82% |
| 2004 Q1 | - AUD | 100.0% |
| 2004 Q2 | 2.51 Million AUD | 0.0% |
| 2004 Q3 | - AUD | -100.0% |
| 2003 FY | 5.6 Million AUD | -3.22% |
| 2003 Q2 | 1.83 Million AUD | 0.0% |
| 2003 Q1 | - AUD | 0.0% |
| 2003 Q3 | - AUD | -100.0% |
| 2003 Q4 | -5.6 Million AUD | 0.0% |
| 2002 FY | 5.78 Million AUD | 64.62% |
| 2001 FY | 3.51 Million AUD | 733.56% |
| 2000 FY | 421.93 Thousand AUD | 627.42% |
| 1999 FY | -80 Thousand AUD | -11494.2% |
| 1998 FY | -690.00 AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 29.55 Million USD | 20.798% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -364.23% |
| CSL Limited | 3.44 Billion USD | 99.321% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 37.173% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2434.536% |
| BioStem Technologies, Inc. | 22.97 Million USD | -1.88% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -115.392% |
| Qrons Inc. | 643.67 Thousand USD | -3536.403% |
| Nascent Biotech, Inc. | 2.22 Million USD | -949.684% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 59.25% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -248.417% |
| Skye Bioscience, Inc. | 13.54 Million USD | -72.774% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -5533.664% |
| Rebus Holdings, Inc. | 664 Thousand USD | -3425.104% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -46.198% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1652.744% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.164% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -5908.402% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 73.029% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -375.948% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -8843.204% |
| SQZ Biotechnologies Company | 85.61 Million USD | 72.662% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -702.634% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1458.473% |
| Mesoblast Limited | 5.9 Million USD | -296.589% |
| Marizyme, Inc. | 19.23 Million USD | -21.657% |
| Genus plc | 147.7 Million USD | 84.153% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -166.614% |
| Pharming Group N.V. | 225.49 Million USD | 89.62% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1042.511% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1644.756% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -180.689% |
| ContraFect Corporation | 56.88 Million USD | 58.856% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -430.924% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1482.868% |
| IMV Inc. | 37.7 Million USD | 37.928% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -738.842% |
| MultiCell Technologies, Inc. | 567.42 USD | -4125008.385% |
| ONE Bio Corp. | 6.44 Million USD | -263.238% |
| Accustem Sciences Inc. | 3.74 Million USD | -524.775% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 72.766% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -4300.068% |
| Q BioMed Inc. | 3.43 Million USD | -581.095% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 5.294% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -790.828% |
| Biomind Labs Inc. | 994.18 Thousand USD | -2254.367% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 76.435% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1230.169% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1155.475% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 93726.76% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1175.503% |
| GB Sciences, Inc. | 1.42 Million USD | -1547.768% |
| Alpha Cognition Inc. | 9.7 Million USD | -141.167% |
| HST Global, Inc. | 140.9 Thousand USD | -16511.446% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1980.761% |
| Halberd Corporation | 74.84 Thousand USD | -31174.806% |
| Enzolytics Inc. | 2.17 Million USD | -973.944% |
| Agentix Corp. | 1.37 Million USD | -1606.33% |
| Resverlogix Corp. | 12.71 Million USD | -84.131% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -541.155% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.474% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2142.02% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -873.278% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1382.041% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -587.425% |
| AVAX Technologies, Inc. | 7.31 Million USD | -220.189% |
| Zenith Capital Corp. | 8.94 Million USD | -161.732% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -134259.049% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -853.306% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -13547.5% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1118.523% |
| Kadimastem Ltd | 2.41 Million USD | -871.187% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1086.931% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -12797.314% |
| LadRx Corporation | 3.81 Million USD | -514.06% |
| Cell Source, Inc. | 4.32 Million USD | -441.152% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2434.536% |
| NovAccess Global Inc. | 2.46 Million USD | -848.884% |
| Affymax, Inc. | 39.38 Million USD | 40.571% |
| Itoco Inc. | 919.14 Thousand USD | -2446.578% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -452.251% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1991.751% |
| Mobile Lads Corp. | 554.54 Thousand USD | -4120.874% |
| CytoDyn Inc. | 18.05 Million USD | -29.62% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -92898.093% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -10535.634% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1548.6% |
| SYBLEU INC | 160.87 Thousand USD | -14449.523% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1188.688% |
| International Stem Cell Corporation | 5.27 Million USD | -344.065% |
| Bioxytran, Inc. | 3.82 Million USD | -512.717% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -44363.907% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -114960.168% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 35.458% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1346.643% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -3080.97% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -652.385% |
| Neutra Corp. | 243.82 Thousand USD | -9499.948% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -34.082% |
| PureTech Health plc | 144.59 Million USD | 83.812% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -14.235% |
| IXICO plc | 4.7 Million USD | -397.274% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -166.076% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 80.121% |
| CSL Limited | 3.89 Billion USD | 99.399% |
| Cellectis S.A. | 97.32 Million USD | 75.949% |